TRENTON, N.J. (AP) -- A cheaper version of Johnson amp;amp; Johnsonamp;apos;s top-selling drug, the pricey rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled that a key patent on the drug is invalid....